Page last updated: 2024-09-05

sorafenib and er-086526

sorafenib has been researched along with er-086526 in 2 studies

Compound Research Comparison

Studies (sorafenib)	Trials (sorafenib)	Recent Studies (post-2010) (sorafenib)	Studies (er-086526)	Trials (er-086526)	Recent Studies (post-2010) (er-086526)
6,520	730	5,251	567	113	517

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Eucker, J; Gomez-Roca, C; Graudenz, K; Huang, F; Lettieri, J; Marmé, F; Peña, C; Trnkova, ZJ	1
Hayashi, K; Igarashi, K; Miwa, S; Takeuchi, A; Tsuchiya, H; Yamamoto, N	1

Reviews

1 review(s) available for sorafenib and er-086526

Article	Year
Therapeutic Targets for Bone and Soft-Tissue Sarcomas. International journal of molecular sciences, 2019, Jan-04, Volume: 20, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Drug Therapy; Furans; Humans; Immunotherapy, Adoptive; Indazoles; Ipilimumab; Ketones; Nivolumab; Osteosarcoma; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Trabectedin	2019

Article

Year

Therapeutic Targets for Bone and Soft-Tissue Sarcomas.

International journal of molecular sciences, 2019, Jan-04, Volume: 20, Issue:1

Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Drug Therapy; Furans; Humans; Immunotherapy, Adoptive; Indazoles; Ipilimumab; Ketones; Nivolumab; Osteosarcoma; Progression-Free Survival; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Trabectedin

2019

Trials

1 trial(s) available for sorafenib and er-086526

Article	Year
Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors. Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Furans; Humans; Ketones; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Salvage Therapy; Sorafenib; Survival Rate; Young Adult	2018

Article

Year

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.

Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:4

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Furans; Humans; Ketones; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Prognosis; Salvage Therapy; Sorafenib; Survival Rate; Young Adult

2018